Literature DB >> 23527718

The role and clinical significance of YES-associated protein 1 in human osteosarcoma.

Y-H Zhang1, B Li, L Shen, Y Shen, X-D Chen.   

Abstract

Yes-associated protein 1 (YAP1) is an oncogene that plays multiple roles in the tumorigenesis and progression of many malignances. The present study aimed to investigate the clinical significance of YAP1 expression in human osteosarcoma (OS) and explore the molecular mechanisms of YAP1 activity in OS MG-63 cells. The expression of YAP1 was assessed by immunohistochemical assay using a tissue microarray procedure. A loss-of-function approach was used to investigate the effects of small hairpin RNA-mediated knockdown of YAP1 on the expression of RUNX2, CyclinD1, and matrix metalloproteinase-9 (MMP-9) as well as the proliferative activities and invasive potential in OS MG-63 cells (evaluated by MTT and Transwell assays, respectively). The expression of YAP1 protein in OS tissues was significantly higher than that in ANCT, and was closely associated with gender (P = 0.013) and Enneking staging (P = 0.035), but it did not correlate with age, tumor location, or distant metastases of OS patients (P greater than 0.05, each). Knockdown of YAP1 resulted in downregulation of the expression of RUNX2, CyclinD1, and MMP-9 and inhibited the proliferation and invasion of MG-63 cells. Our findings suggest that YAP1 is highly expressed in OS tissues, and increased expression of this molecule is correlated with the gender and Enneking staging of osteosarcoma patients. Knockdown of YAP1 may inhibit the proliferation and invasion of OS cells through downregulation of the RUNX2 pathway, thereby representing a potential therapeutic target for the treatment of cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527718     DOI: 10.1177/039463201302600115

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  23 in total

Review 1.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

2.  Expression of Yes-associated protein (YAP) in breast phyllodes tumor.

Authors:  Sang Kyum Kim; Woo Hee Jung; Ja Seung Koo
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  The mevalonate pathway promotes the metastasis of osteosarcoma by regulating YAP1 activity via RhoA.

Authors:  Xing Du; Yunsheng Ou; Muzi Zhang; Kai Li; Wei Huang; Dianming Jiang
Journal:  Genes Dis       Date:  2020-11-21

4.  Abemaciclib Is Effective Against Pancreatic Cancer Cells and Synergizes with HuR and YAP1 Inhibition.

Authors:  Teena Dhir; Christopher W Schultz; Aditi Jain; Samantha Z Brown; Alex Haber; Austin Goetz; Chunhua Xi; Gloria H Su; Liang Xu; James Posey; Wei Jiang; Charles J Yeo; Talia Golan; Michael J Pishvaian; Jonathan R Brody
Journal:  Mol Cancer Res       Date:  2019-08-05       Impact factor: 5.852

Review 5.  YAP/TAZ at the Roots of Cancer.

Authors:  Francesca Zanconato; Michelangelo Cordenonsi; Stefano Piccolo
Journal:  Cancer Cell       Date:  2016-06-13       Impact factor: 31.743

6.  Loss of large tumor suppressor 1 promotes growth and metastasis of gastric cancer cells through upregulation of the YAP signaling.

Authors:  Jing Zhang; Ge Wang; Shao-Jun Chu; Jin-Shui Zhu; Rui Zhang; Wen-Wen Lu; Li-Qiong Xia; Yun-Min Lu; Wei Da; Qun Sun
Journal:  Oncotarget       Date:  2016-03-29

7.  Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.

Authors:  Corinne Bouvier; Nicolas Macagno; Quy Nguyen; Anderson Loundou; Carine Jiguet-Jiglaire; Jean-Claude Gentet; Jean-Luc Jouve; Alexandre Rochwerger; Jean-Camille Mattei; Daniel Bouvard; Sébastien Salas
Journal:  Oncotarget       Date:  2016-10-04

8.  Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.

Authors:  Ana Gvozdenovic; Aleksandar Boro; Daniela Meier; Beata Bode-Lesniewska; Walter Born; Roman Muff; Bruno Fuchs
Journal:  Oncotarget       Date:  2016-08-23

Review 9.  A Review: Molecular Aberrations within Hippo Signaling in Bone and Soft-Tissue Sarcomas.

Authors:  Michael D Deel; Jenny J Li; Lisa E S Crose; Corinne M Linardic
Journal:  Front Oncol       Date:  2015-09-02       Impact factor: 6.244

10.  Antitumor activity of dobutamine on human osteosarcoma cells.

Authors:  Jun Yin; Qirong Dong; Minqian Zheng; Xiaozu Xu; Guoyou Zou; Guolin Ma; Kefeng Li
Journal:  Oncol Lett       Date:  2016-04-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.